Compare EVI & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVI | ICUCW |
|---|---|---|
| Founded | 1959 | N/A |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.9M | N/A |
| IPO Year | N/A | 2021 |
| Metric | EVI | ICUCW |
|---|---|---|
| Price | $25.80 | $0.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $40.00 | N/A |
| AVG Volume (30 Days) | ★ 17.5K | N/A |
| Earning Date | 02-09-2026 | N/A |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $404,474,000.00 | N/A |
| Revenue This Year | $13.65 | N/A |
| Revenue Next Year | $4.49 | N/A |
| P/E Ratio | $65.69 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $14.99 | N/A |
| 52 Week High | $34.82 | N/A |
| Indicator | EVI | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 68.44 | 39.98 |
| Support Level | $22.52 | $0.01 |
| Resistance Level | $26.80 | $0.01 |
| Average True Range (ATR) | 1.13 | 0.00 |
| MACD | 0.64 | 0.00 |
| Stochastic Oscillator | 98.25 | 50.00 |
EVI Industries Inc through its subsidiaries, is a distributor that sells, leases, and rents commercial, industrial, and vended laundry and dry cleaning equipment and steam and hot water boilers manufactured by others, supplies related replacement parts and accessories, designs and plans turn-key laundry, dry cleaning, and boiler systems, and provides installation and maintenance services to its customers, which include commercial, industrial, institutional, government, and retail customers. These activities are conducted in the United States, Canada, the Caribbean, and Latin America.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.